Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...
“We are pleased the FDA has declared that supply of the only real, FDA-approved semaglutide medicines is resolved, affirming ...
The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...
In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., also had been resolved. Zepbound is approved to treat obesity and Mounjaro ...
The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...
Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...
Companies argue they’re filling a need created by these miracle weight-loss drugs. But are they offering something of real value — or simply taking advantage of another food fad?
U.S. stock futures were little changed on Thursday night after the major averages slid following a lackluster earnings ...